Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
Leukemia
.
2016 Oct;30(10):2080-2083.
doi: 10.1038/leu.2016.120.
Epub 2016 May 2.
Authors
M Othus
1
,
B L Wood
2
,
D L Stirewalt
3
4
,
E H Estey
3
5
,
S H Petersdorf
3
4
,
F R Appelbaum
3
4
,
H P Erba
6
,
R B Walter
3
5
7
Affiliations
1
SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
2
Division of Hematopathology, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
3
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
4
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
5
Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA.
6
Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
7
Department of Epidemiology, University of Washington, Seattle, WA, USA.
PMID:
27133827
PMCID:
PMC5053842
DOI:
10.1038/leu.2016.120
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Adult
Humans
Leukemia, Myeloid, Acute / pathology*
Neoplasm, Residual*
Recurrence
Survival Analysis
Grants and funding
U10 CA180801/CA/NCI NIH HHS/United States
R01 CA160872/CA/NCI NIH HHS/United States
U10 CA180828/CA/NCI NIH HHS/United States
U10 CA180944/CA/NCI NIH HHS/United States
R21 CA182010/CA/NCI NIH HHS/United States
U10 CA180855/CA/NCI NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
R01 CA090998/CA/NCI NIH HHS/United States